Evidence map›Paper›PMID 32701386›Full record

ArticleHuman vaccines & immunotherapeutics2021

Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States.

Eric Adjei Boakye, Nosayaba Osazuwa-Peters, Julia López, Vy T Pham, Betelihem B Tobo, Leping Wan, Mario Schootman, Jane A McElroy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric Adjei BoakyeDepartment of Population Science and Policy, Southern Illinois University School of Medicine , Springfield, IL, USA.ORCID 0000-0001-9163-8103
Nosayaba Osazuwa-PetersDepartment of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine , St. Louis, MO, USA.ORCID 0000-0002-1390-9753
Julia LópezDepartment of Obstetrics & Gynecology, Washington University School of Medicine , St. Louis, MO, USA.ORCID 0000-0002-8197-002X
Vy T PhamDepartment of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine , St. Louis, MO, USA.ORCID 0000-0003-2305-7096
Betelihem B ToboCommunity Health Administration, DC Health , Washington, DC, USA.
Leping WanDepartment of Radiation Oncology, Washington University School of Medicine , St. Louis, MO, USA.
Mario SchootmanCenter for Clinical Excellence, SSM Health , Saint Louis, MO, USA.ORCID 0000-0003-1162-8824
Jane A McElroyFamily and Community Medicine Department, University of Missouri , Columbia, MO, USA.ORCID 0000-0001-7518-747X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe compared HPV vaccine initiation and completion of heterosexual with lesbian and bisexual (LB) women.

methodsWe aggregated National Health and Nutrition Examination Survey data from 2009 to 2016 for 3,017 women aged 18 to 34 y in the United States. HPV vaccine initiation was defined as reported receipt of ≥1 dose of the vaccine and completion as receipt of the three recommended doses. Weighted percentages and multivariable logistic regression models were used to examine differences in HPV vaccine initiation and completion between heterosexual and LB women.

resultsApproximately 12% of respondents self-identified as LB women. Overall, a higher percentage of respondents (26%) had initiated the HPV vaccine than completed the three vaccine doses (17%). In the bivariate analysis, LB women had higher initiation ([35% of LB women versus 25% heterosexual];

conclusionsAlthough LB women had higher likelihood of HPV vaccine initiation and completion compared with heterosexual women, their HPV vaccine uptake was well below the Healthy People 2020 target (80%). Understanding differences in the drivers of vaccine uptake in the LB population may inform strategies that would further increase HPV vaccine uptake toward achieving the 80% completion target.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsPapillomavirus VaccinesFemaleHumansNutrition SurveysSexual BehaviorUnited StatesVaccinationPapillomavirus VaccinesHPV vaccination initiation and completionHPV vaccineHuman papillomaviruslesbian and bisexual womensexual orientationyoung adults

Identifiers

PMID32701386
PMCPMC7899676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.